Group 1 - Salem Media Group, Inc. announces the launch of a new podcast "Unshaken and Unafraid" hosted by Joe Pags, featuring three episodes per week [1][2] - The podcast represents a significant step in Salem Media's mission to provide trusted conservative content across various platforms [2][6] - Joe Pags is recognized for his bold commentary and has a history of interviewing high-profile figures, including President Donald J. Trump [2][5] Group 2 - The podcast aims to deliver exclusive interviews and insights into stories often overlooked by mainstream media [6] - Joe Pags emphasizes that the podcast is a platform for genuine discussion in a media landscape filled with propaganda [6] - Salem Media Group is a leading multimedia company focused on Christian and conservative content, serving millions of dedicated listeners and viewers [7][8]

Core Insights - CMI Media Group's Empower™ SaaS-operating system's automated media orchestration (AMO) application has successfully executed over 200 campaigns, generating $1 billion in incremental revenue for more than 25 clients [1][2][3] Company Overview - CMI Media Group is a global, full-service media agency focused exclusively on health, wellness, and pharmaceutical marketing, offering services such as Audience Strategy, Data and Analytics, and Customer Experience [7] - The agency has established itself as a premier healthcare-focused media planning resource, leveraging innovative technology and data to enhance healthcare marketing [6][7] Product Features - The AMO application addresses the challenge of orchestrating paid media at scale, integrating seamlessly with client marketing technology stacks to support owned media, web personalization, and CRM [2][5] - Empower OS is the first integrated operating system that connects healthcare professionals and consumers, embedding predictive capabilities and AI for data-driven media strategies [5] Future Developments - CMI Media Group plans to launch a Consumer (DTC) option that will be fully privacy-compliant, further bridging the gap between healthcare professionals and consumers [4]

Core Insights - Salem Media Group, Inc. is launching a new podcast titled "Unshaken and Unafraid" hosted by Joe Pags, featuring three episodes per week [1][2] - The podcast aims to provide a platform for conservative voices and tackle stories often overlooked by mainstream media [5][6] - Joe Pags is recognized for his bold commentary and has a history of interviewing high-profile figures, including President Donald J. Trump [2][6] Company Overview - Salem Media Group is a leading multimedia company in the U.S. specializing in Christian and conservative content, with a diverse portfolio including radio, digital media, and publishing [7] - The company serves millions of dedicated listeners, readers, and viewers daily, focusing on compelling audio and video programming [7] Podcast Features - "Unshaken and Unafraid" will include exclusive interviews, bold commentary, and insights into underreported stories [6] - The podcast is positioned as a response to perceived censorship and aims to amplify conservative perspectives [5][6]

Core Insights - IMUNON, Inc. announced promising Overall Survival data from the Phase 2 OVATION 2 Study of IMNN-001 for treating newly diagnosed advanced ovarian cancer, which will be presented at the 2025 ASCO Annual Meeting [1][3] - The company has aligned with the FDA on the Phase 3 OVATION 3 clinical trial protocol for IMNN-001 and has begun activating trial sites [1][3] Company Overview - IMUNON is a clinical-stage biotechnology company focused on developing innovative treatments using its proprietary TheraPlas technology platform, which enables gene-based delivery of cytokines for cancer treatment [9][10] - The lead clinical program, IMNN-001, is a DNA-based immunotherapy designed to produce interleukin-12 and interferon gamma at the tumor site, targeting advanced ovarian cancer [10] Study Details - The OVATION 2 Study evaluated the safety and efficacy of intraperitoneal IMNN-001 combined with neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer, enrolling 112 patients [5][6] - The study was not powered for statistical significance but included endpoints such as objective response rate and surgical response [6] Treatment Context - Epithelial ovarian cancer is a significant health concern, with approximately 20,000 new cases annually in the U.S., and about 70% diagnosed at advanced stages [8] - The five-year survival rates for patients with Stage III/IV ovarian cancer are low, highlighting the need for innovative therapies that improve overall survival and reduce recurrence rates [8]

作为Meta最重要的收入来源之一，Instagram在2020年和2021年分别创造了220亿美元和324亿美元的 广告收入。 然而TikTok的崛起正在动摇这一核心业务的增长基础。为应对挑战，Meta正式推出短视 频功能Reels，并将其成功标准设定为：到2024年，Reels的用户使用时长需达到TikTok在2020年水平 的一半，即每位日活跃用户日均使用77分钟，预计可带来60亿美元收入。 参考资料 [1] https://www.theinformation.com/briefings/2020-instagram-projected-billions-lost-revenue-tiktok?rc=o6xpry 欢迎扫码加群参与讨论 图片来源： Unsplash 在Meta反垄断诉讼庭审的关键阶段，一份提交给董事会的内部分析报告被当庭披露，揭示了TikTok对 Instagram造成的深远影响。报告显示，由于TikTok的强势竞争，Instagram核心功能的使用时长和收 入增长均遭受重创。 根据这份2020年下半年的分析预测，Instagram动态和Stories功能的使用时长较2019年预期下降5 ...

CHICAGO, April 07, 2025 (GLOBE NEWSWIRE) -- Sprout Social, Inc. (“Sprout Social”, the “Company”) (Nasdaq: SPT), an industry-leading provider of cloud-based social media management software, today announced that it will report its financial results for the first quarter ending March 31, 2025 after market close on Thursday, May 8, 2025. The financial results and business highlights will be discussed on a conference call and webcast scheduled at 4:00 p.m. Central Time (5:00 p.m. Eastern Time) on Thursday, May ...

Contacts: David K. Waldman-US Investor Relations Crescendo Communications, LLC (212) 671-1021 The 11th Annual Waste & Environmental Services Symposium draws companies with a focus on the themes of waste, water treatment, and the environment. This timely conference will feature presentations by senior management of leading companies, with an emphasis on industry dynamics, new technologies, and company fundamentals. To register to attend the symposium, please follow this link. About Perma-Fix Environmental Se ...

Direct Digital Holdings, Inc. (NASDAQ:DRCT) Q4 2024 Earnings Conference Call March 27, 2025 5:00 PM ET Corporate Participants Brett Milotte - Investor Relations, ICR Mark Walker - Chairman and Chief Executive Officer Diana Diaz - Chief Financial Officer Conference Call Participants Dan Kurnos - The Benchmark Company Michael Kupinski - NOBLE Capital Markets Operator Thank you for standing by. Welcome to the Direct Digital Holdings Fourth Quarter and Full Year 2024 Earnings Call. All lines have been placed on ...

Financial Data and Key Metrics Changes - The company reported encouraging clinical data for MRT-6160, mapping a clear path to Phase 2 studies, with a focus on achieving over 80% degradation of VAV1 and cytokine modulation between 82% to 99% [37][62]. - The company maintains a strong balance sheet, providing a cash runway anticipated into 2028 [65]. Business Line Data and Key Metrics Changes - MRT-6160 demonstrated a dose-dependent pharmacokinetic profile with over 90% VAV1 degradation in T cells after administration, consistent with preclinical studies [15][20]. - The NEK7 program is on track for an IND submission in the first half of the year, with plans for clinical proof of concept trials in various inflammatory conditions [26][64]. Market Data and Key Metrics Changes - The company is focusing on the oncology market, particularly in castration-resistant prostate cancer, where early signs of clinical response have been observed [51][54]. - The NEK7 program targets the NLRP3 inflammasome, which is critical in many inflammatory conditions, indicating a broad potential market for the drug [24][34]. Company Strategy and Development Direction - The company aims to expand its portfolio of oral immunology and inflammation (I&I) drugs, leveraging its clean platform for drug discovery [35][62]. - There is a strategic focus on developing MRT-2359 for prostate cancer, with plans to prioritize this indication over others due to its significant unmet need [54][63]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the safety profile of MRT-6160, with no serious adverse events reported in the Phase 1 study [20][21]. - The management is optimistic about the potential of MRT-8102 and plans to submit an IND in the first half of the year, indicating a proactive approach to clinical development [64][65]. Other Important Information - The company has established a strategic development agreement with Novartis for MRT-6160, aiming to accelerate its development [10][11]. - The preclinical data for MRT-8102 shows a favorable safety margin, supporting its advancement into clinical trials [30][31]. Q&A Session Summary Question: On VAV1, how does the company decide on the most promising indications to pursue? - The company is still preparing for Phase 2 studies, with preclinical data suggesting strong potential in indications driven by T and B cells, such as ulcerative colitis and rheumatoid arthritis [70][71]. Question: How does ex vivo simulation differ from in vivo measurement? - The company indicated that the exact percentage of in vivo biomarker reduction will depend on the disease type, but they are confident in the molecule's ability to achieve significant effects in patients [74][75]. Question: What is the ideal application for MRT-2359 in prostate cancer? - The company sees potential in targeting both castrate-resistant and castrate-sensitive prostate cancer, with a focus on combinations with androgen receptor inhibitors [78][80]. Question: How does the company compare its cytokine inhibition to other therapies? - The company believes it compares favorably to BTK inhibitors and IL-17 antagonists, achieving up to 99% inhibition in healthy volunteers [89][90]. Question: What are the interim factors for expanding the prostate cancer cohort? - The company mentioned an interim efficacy assessment is in place before expanding enrollment, considering the heavily pretreated nature of the patient population [92][93]. Question: What are the expected on-target side effects for VAV1? - The company does not anticipate significant on-target toxicities based on preclinical data, but acknowledges a potential risk of infections [105][106]. Question: How does GSPT1 degradation correlate with clinical activity? - The company noted that the responder in the biomarker-positive group was a neuroendocrine bladder cancer patient, indicating that high N-MYC expression is a good target, although such patients are rare [108][109].

Financial Data and Key Metrics Changes - The company completed its 2022 restatement and is on track to become current with its filing obligations [6][8] - For 2023, estimated GAAP revenue is projected to be between $620 million and $625 million, with recurring revenue making up approximately 80% of total revenue [23][24] - Adjusted EBITDA for 2023 is estimated to be between $139 million and $144 million, which is higher than previously estimated [24] - For 2024, GAAP revenue is estimated to be between $583 million and $588 million, with a recurring revenue percentage consistent with prior years [27] - Adjusted EBITDA for 2024 is estimated to be between $85 million and $90 million, below previous guidance [29][30] Business Line Data and Key Metrics Changes - Provider business revenue dipped by 1% year-over-year, while payer and life sciences revenue declined by 10% [27][28] - The company signed significant contracts in its provider business, including a multimillion-dollar deal with a large urology practice and a major wound care organization [13][14] - The payer business saw the onboarding of nearly 400 new sites in 2025, with care gap alerts provided to over 3,500 healthcare practices [14] Market Data and Key Metrics Changes - The company experienced unexpected revenue shortfalls in the payer and life sciences segments, particularly in Q4 of 2024 [26][68] - The life sciences segment saw softness in media revenue and real-world data sales, while the payer segment faced implementation delays [68] Company Strategy and Development Direction - The company aims to remediate material weaknesses and enhance internal controls while executing its growth strategy [15][36] - The focus is on expanding the core provider base and enhancing the value of offerings, including AI-enabled workflows [15][16] - The company is pursuing additional debt financing to ensure liquidity and support future growth [80] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business model despite revenue shortfalls and emphasized the importance of operational improvements [12][36] - The outlook for 2025 anticipates flat revenue compared to 2024, with expectations of growth from new customers offset by customer attrition [32][58] - Management noted that the remediation efforts and regaining current filing status are expected to occur in 2026 [33][41] Other Important Information - The company incurred significant external audit and legal fees in 2023 and 2024, impacting cash flow [9][30] - The acquisition of Science.io and Koa Health is expected to impact EBITDA margins due to new costs associated with these businesses [101][102] Q&A Session Summary Question: Clarification on remediation efforts and filing status - Management clarified that remediation efforts can continue while regaining currency on filings, with both expected to occur in 2026 [38][40] Question: Net attrition in provider business - Higher net attrition was noted in the core provider business, particularly in revenue cycle management, but not driven by market consolidation [44][46] Question: Revenue visibility for FY 2025 - Management indicated that while revenue is expected to be flat, there are uncertainties due to customer attrition and the need for a rebound from the previous year's shortfall [60][63] Question: Trends in life sciences and pharma segment - Management noted softness in media revenue but observed a pickup in spending in Q1 2025, indicating potential recovery in the life sciences segment [89] Question: Impact of acquisitions on financials - The acquisition of Science.io is not expected to contribute revenue in 2024, but it is seen as a strategic investment in AI capabilities [97][100]